In humans with FXS, the loss of FMRP results in a variety of neurological symptoms widely associated with imbalances in excitation/inhibition and dysfunctional plasticity in critical brain regions such as the cortex, hippocampus, and amygdala. The gene discussed is FMR1; the disease is fragile X syndrome.